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Objective. To clarify whether time lapsing from advent of fever as a ﬁrst sign of sepsis may be indicative of the potency of mono-
cytes for the release of pro- and anti-inﬂammatory mediators. Methods. Monocytes were isolated from blood of 51 septic patients
and 9 healthy donors. Monocytes were incubated in the absence and presence of patients’ serum and concentrations of tumour
necrosis factor-alpha (TNFα), interleukin (IL)-6, IL-10, and malondialdehyde (MDA) were estimated in supernatants. Patients
were divided into three groups: group A: <12hours, group B: 12–24hours, and group C: >24hours between initiation of fever and
blood sampling. Results.T N F α of supernatants of groups B and C was higher than controls, as also were IL-6 of A and C, IL-10 of
A and B, and MDA of A. IL-6 of group A was increased after addition of patients serum. A negative correlation was found between
time from initiation of symptoms and IL-6 of monocyte supernatants incubated in the presence of patients serum. Median IL-6 of
survivorswashigherthannonsurvivors.Conclusion.Monocytesarepotentforthereleaseofpro-andanti-inﬂammatorymediators
within the ﬁrst 24hours upon advent of fever related to sepsis; serum stimulates further release of IL-6 within the ﬁrst 12hours.
Copyright © 2008 Magdalini Kyriakopoulou et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Despite the increase of knowledge on the mechanisms of
pathogenesis of sepsis, its mortality remains high making
sepsis the ninth cause of death in Northern Europe and in
the United States [1]. The increased incidence of the sep-
tic syndrome has focused attention on various strategies
for its management. Among these strategies, immunother-
apies have been evolved. These comprised antibodies tar-
geted against tumour necrosis factor-alpha (TNFα)a n de n -
dotoxins, soluble receptors of TNFα, plasma hemodialysis,
inhibitors of nitric oxide synthase, and activated protein C.
Whereas most of them were successful when used in phase
II clinical trials, they have either failed or proved problem-
atic when applied in phase III clinical trials [2, 3]. Various
hypotheses have been proposed to explain the failure of im-
munotherapies. The most important seems to be the lack of
in-depth knowledge of the pathogenesis of sepsis [4]. Cur-
rent theories of pathogenesis are based on the production
of proinﬂammatory and anti-inﬂammatory cytokines after
stimulation of blood monocytes by bacterial products and
immunotherapies are often targeted against these mediators.
However, in all clinical trials, therapies were administered
upon fulﬁlment of certain criteria of enrolment without fully
knowing the immunological status of the host on the time of
start of any investigational product [4].
The importance of administration of immunotherapy
on the time period when proinﬂammatory mediators reach
their peak has been underscored by experimental studies [5].
To achieve that in the clinical ﬁeld, it is mandatory to be
able to correlate the presence of symptoms with the func-
tion of the immune system. Monocytes of septic patients
are often deactivated, that is, they produce limited amounts
of proinﬂammatory mediators when stimulated by bacterial
products [6]. However, no data are available if monocytes of
septic patients are capable to produce proinﬂammatory and2 Mediators of Inﬂammation
anti-inﬂammatory mediators when transferred ex vivo. The
present study attempted to provide such information and to
correlate the ex vivo release of mediators from monocytes
with the time lapsing from the initiation of fever as a ﬁrst
sign of sepsis.
2. PATIENTS AND METHODS
2.1. Characteristicsofpatients
Enrolment took place over the period January-September
2003 when the 4th Department of Internal Medicine was sit-
uated in “Sismanoglion” General Hospital of Athens. The
protocol was approved by the Ethics Committee of the Sis-
manoglion General Hospital; written informed consent was
taken from the patients or ﬁrst-degree relatives. All consec-
utive admissions to the emergency department were eligible
for the study.
Inclusioncriteriawere(a)thepresenceoffeverdeﬁnedas
body temperature greater than 38◦C being the ﬁrst symptom
of the underlying infection, (b) presence of one of the fol-
lowing underlying infections: lower respiratory tract infec-
tion, intrabdominal infection, or acute pyelonephritis, and
(c) sepsis, severe sepsis, or septic shock. Exclusion criteria
were: (a) HIV infection, (b) neutropenia deﬁned as less 1000
neutrophils/μL, and (c) intake of corticosteroids at a dose
greater than or equal to 1mg/kg of equivalent prednisone for
more than one month.
Lower respiratory tract infection was deﬁned as the pres-
ence of all of the following [7]: (a) core temperature > 38◦C,
(b) new or increased cough, (c) new or increased purulent
sputum production; and (d) new inﬁltrate on chest X-ray.
Intrabdominal infection was deﬁned as the presence of
all of the following [8]: (a) core temperature > 38◦C, (b)
pain on deep palpation, (c) radiological ﬁndings compatible
with intra-abdominal infection, and (d) white blood cells >
12,000/μLo r<4,000/μLo r>10% of band forms.
Acute pyelonephritis was deﬁned as the presence of all
of the following [9]: (a) core temperature > 38◦C, (b) lum-
bartendernessorradiologicalﬁndingscompatiblewithacute
pyelonephritis, and (c) more than 10 white blood cells phf of
centrifuged urine.
Sepsis was deﬁned as the presence of an infection accom-
panied by at least two of the following [10]: (a) body tem-
perature greater than 38◦C, (b) respiratory rate higher than
20 breaths/min or PCO2 < 32mmH, (c) heart rate above 90
beats/min, and (d) white blood cells > 12,000 or <4,000/μL
or more than 10% bands.
Severe sepsis was deﬁned as sepsis complicated by the
acute dysfunction of at least one organ due to an underly-
ing infection, that is, the acute presentation of at least one of
the following [10]:
(i) acute respiratory distress syndrome (ARDS): pO2/
FiO2 below 200 with diﬀuse bilateral shadows in lung
X-ray;
(ii) acute renal failure: urine production less than
0.5mL/Kg body weight/h for at least two hours pro-
vided that the negative ﬂuid balance of the patient was
restored;
(iii) metabolic acidosis: pH < 7.30 or any base deﬁcit
greater than 5mEq/L and serum lactate at least more
than 2x normal value;
(iv) acute coagulopathy: platelet count < 100.000/μLo r
INR > 1.5.
Septic shock was deﬁned as sepsis complicated with sys-
tolicbloodpressurebelow90mmHgformorethanonehour
requiring the administration of vasopressors provided that
the negative ﬂuid balance of the patient is corrected [10].
Twenty ﬁve mL of whole blood were sampled from each
patient after puncture of a peripheral vein under sterile con-
ditions before initiation of any antimicrobial therapy; 20mL
were collected into a heparin-coated and sterile tube (Becton
Dickinson, Coskeysville, Md, USA) and the remaining into a
sterile tube. The latter was centrifuged and serum was kept at
–70◦C until assayed.
For each patient the following were recorded: age, sex,
time interval between initiation of fever and blood sampling,
as well as APACHE II score and outcome. The exact time of
presentation of fever was provided by the patient’s history.
Nonreliable patients were not considered eligible.
2.2. Laboratorytechniques
For the isolation of peripheral blood mononuclear cells
(PBMCs), heparinized venous blood was layered over Fi-
coll Hypaque (Biochrom, Berlin, Germany) and centrifuged.
The separated mononuclear cells were washed three times
with PBS (pH 7.2) and resuspended in RPMI 1640 supple-
mented with 2mM of glutamine (Biochrom) in the pres-
ence of 100U/mL of penicillin G and 0.1mg/mL of strep-
tomycin (Sigma-Aldrich, Miss, USA). After incubation for
1h o u ra t3 7 ◦Ci n5 %C O 2,n o n a d h e r e n tc e l l sw e r er e -
moved while adherent monocytes were washed three times
with Hank’s solution. Cells were then harvested by 0.25%
trypsin/0.02%EDTA(Biochrom)andcountedinaNeubauer
plate after trypan blue exclusion. Their purity in monocytes
wasmorethan95%asdeﬁnedafterincubationwiththeanti-
CD14 mononuclear antibody at the ﬂuorocolour FITC (Im-
munotech, Marseille, France) and analysis by the EPICS/XL
ﬂow cytometer (Beckman Coulter Inc., Miami, Fl, USA) us-
ing IgG-FITC-stained cells as negative controls.
Half of cells were treated with an ice-cold cell lysis buﬀer
(50mM HEPES, 0.1% CHAPS, 5mM DTT, 0.1mM EDTA,
pH 7.4). After centrifugation for ten minutes at 10,000g un-
der 4◦C, activity of caspase-3 was estimated in the cytosolic
extract by an enzymatic chromogenic assay (BIOMOL Re-
search Laboratories, Plymouth, Pa, USA). It was based on
the rate of hydrolysis at 37◦C of a substrate releasing p-
nitroaniline overtime, as assessed by sequential photometry
at 410nm. The assay was also performed in the presence of a
caspase-3 inhibitor. The activity of caspase-3 in cell extracts
was expressed as pmol/min·104 cells.
The remaining half of monocytes were distributed into
two wells of a 12-well plate at a volume of 2.4mL per well
with RPMI 1640 supplemented with 2mM of glutamine.
They were incubated in the absence or presence of 100μLo f
the patient’ serum so that added serum represented 4.1% ofMagdalini Kyriakopoulou et al. 3
Table 1: Demographic characteristics of 51 patients with septic syndrome enrolled in the study.
Sepsis Severe sepsis Septic shock
Number 38 10 3
Male/Female 15/23 3/7 0/3
Age (mean ± SD) 59.8 ±24.87 3 .6 ±12.47 8 .0 ± 7.0
APACHE II score (mean ± SD) 4.7 ±4.61 2 .9 ±6.31 7 .8 ± 7.5
White blood cells (/μl, mean ± SD) 12800.9 ±5366.5 16367.0 ±4734.3 13856.7 ± 2511.7
Underlying infection [no. (%)]
Lower respiratory tract infection 8 (21.1) 4 (40.0) 0
Intrabdominal 12 (31.6) 2 (20.0) 2 (66.7)
Acute pyelonephritis 18 (47.4) 4 (40.0) 1 (33.3)
Bacteremia [no. (% all enrolled patients)]
Providencia stuartii — 2 (20.0) —
Escherichia coli 4 (10.5) — —
Positive urine cultures (>105 cfu/ml) [no. (%)]
Escherichia coli 16 (42.1) 3 (30.0) 1 (33.3)
Pseudomonas aeruginosa 2 (5.3) 1 (10.0) —
Providencia stuartii — 1 (10.0) —
Administered antimicrobials [no. (%)]
2nd generation cephalosporin 11 (28.9) 1 (10.0) —
2nd generation cephalosporin + metronidazole 10 (10.5) 2 (20.0) —
Ceftriaxone + macrolide 8 (21.1) 4 (40.0) —
Piperacillin/tazobactam + vancomycin 0 3 (30.0) 3 (100)
Amplicilln/sulbactam 9 (23.7) — —
Death (%) 2 (5.3) 1 (10.0) 0 (0)
the total well volume. After 24 hours of incubation at 37◦C
under 5% CO2, the plate was centrifuged and the super-
natants were kept at –70◦C until assayed. Monocytes isolated
from nine healthy donors and incubated only in the absence
of serum were applied as controls.
Concentrations of TNFα, interleukin (IL)-6, and IL-
10 were estimated in serum and supernatants by an en-
zyme immunoabsorbent assay (Diaclone, Paris, France). The
lower detection limits of the assay were 1.5pg/mL for TNFα,
6.25pg/mLforIL-6,and12.5pg/mLforIL-10.Theirconcen-
trations in monocyte supernatants were expressed as pg/104
cells.
Lipid peroxidation was estimated in serum and super-
natants by the concentration of MDA, as already described
[11]. Brieﬂy, a 0.1mL aliquot of each sample was mixed to
0.9mL of trichloroacetic acid 20% (Merck) and centrifuged
at 12,000g and 4◦C for 10 minutes. The supernatant was re-
moved and incubated with 2mL of thiobarbituric acid 0.2%
(Merck) for 60 minutes at 90◦C. After centrifugation, a vol-
ume of 10μL of the supernatant was injected into a high-
performance liquid chromatography system (HPLC, Agi-
lent 1100 Series, Waldbronn, Germany) with the following
characteristics of elution: Zorbax Eclipse XDB-C18 (4.6 ×
150mm, 5μm) column under 37◦C; mobile phase consist-
ing by a 50mM K3PO4 (pH: 6.8) buﬀer and methanol 99%
at a 60/40 ratio with a ﬂow rate of 1mL/min; ﬂuoromet-
ric detection with signals of excitation at 515nm and emis-
sion at 535nm. The retention time of MDA was 3.5 min-
utes and it was estimated by a standard curve created with
1, 1, 3, 3-tetramethoxy-propane (Merck). All determinations
were performed in duplicate. Concentrations were expressed
as μmol/mL of serum and μmol/104 cells of supernatant.
2.3. Statisticalanalysis
Results were expressed as median and 95% conﬁdence inter-
vals (CI) or as interquartile range (IQR). For the purposes
of analysis, patients were divided into three groups accord-
ing to the time interval between initiation of fever and blood
sampling: group A: <12 hours, group B: 12 to 24 hours,
and group C, >24 hours from start of fever. Comparisons
between groups were done by Mann-Whitney U test with
a Bonferroni correction; comparisons of yielded concentra-
tions between absence and presence of serum by Wilcoxon’s
test. Correlations between time interval from sampling and
concentrations of cytokines were performed according to
Spearman’s rank of order. Any value of P below .05 was con-
sidered as signiﬁcant.
3. RESULTS
Over the period of enrolment, 54 patients were eligible. Fifty
one were ﬁnally enrolled because only in them fever was the
ﬁrst symptom for underlying infection. Demographic char-
acteristicsofthesepatientsareshowninTable 1.Sputumcul-
tures failed to disclose any pathogen.4 Mediators of Inﬂammation
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Figure 1: Ex vivo release of tumour necrosis factor-alpha (TNFα), IL-6, IL-10, and malondialdehyde (MDA) by monocytes of 51 patients
with septic syndrome and nine healthy donors. Patients were divided into three groups depending on the time lapsing between blood
sampling and advent of fever: group A: <12 hours group B: 12–24 hours, and group C: >24 hours. Asterisks denote outliers and circles
denote extremes. P values refer to comparisons with controls.
Thirteen patients belonged to group A, 16 patients to
group B, and 22 patients to group C. Concentrations of
TNFα, IL-6, IL-10, and MDA of serum in relation to that
timeintervalareshowninTable 2.N odiﬀerenceswerefound
between groups of time interval.
Concentrations of TNFα, IL-6, IL-10, and MDA of
monocyte supernatants without presence of patients’ serum
inrelationtothetimeintervalofinitiationoffeverfromsam-
pling compared to controls are shown in Figure 1.T N F α of
groups B and C was higher than controls, IL-6 of groups A
and C higher than controls, IL-10 of groups A and B higher
than controls, and MDA of group A higher than controls.
The eﬀect of serum on mediator release is shown in
Figure 2. IL-6 of supernatants of monocytes isolated from
patients of group A was increased after addition of patients’
serum (P = .018). That was the case for MDA of groups BMagdalini Kyriakopoulou et al. 5
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Figure 2:Eﬀectofserumonexvivoreleaseoftumournecrosisfactor-alpha(TNFα),IL-6,IL-10,andmalondialdehyde(MDA)bymonocytes
of 51 patients with septic syndrome. Patients were divided into three groups depending of the time lapsing between blood sampling and
advent of fever: group A: <12 hours, group B: 12–24 hours, and group C: >24 hours. Circles denote extremes.6 Mediators of Inﬂammation
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Figure 3: Correlation between time lapsing from advent of fever to
blood sampling and concentrations of interleukin-6 (IL-6) released
from monocytes of 51 septic patients incubated in the presence of
patients’ serum.
(P = .049) and C (P = .048). IL-6 of supernatants of mono-
cytes grown in the presence of patients’ serum was higher for
group A compared to groups B (P = .037) and C (P = .048).
Median (IQR) activity of caspase-3 was 53.5 (295.5)
pmol/min·104 cells for group A, 200 (2020) pmol/min·104
cells for group B, and 99.6 (1642) pmol/min·104 cells for
group C (pNS between groups of time).
A negative correlation was found between time from ini-
tiation of symptoms and IL-6 of monocyte supernatants in-
cubated in the presence of patients’ serum (rs: −0.353, P =
.041, Figure 3). No other signiﬁcant correlation was found.
Median (IQR) IL-6 of supernatants of monocytes of sur-
vivors was 41.9 (149.2) pg/104 cells compared to 1.9 (67.8)
pg/104 cells of nonsurvivors (P = .048). Respective values
in the presence of serum were 51.6 (96.0) and 37.8 (30.0)
pg/104 (pNS). No diﬀerences were found in concentrations
of TNFα, IL-10, and MDA of monocyte supernatants be-
tween survivors and nonsurvivors.
4. DISCUSSION
The immunological function of the septic patient admit-
ted to the emergencies cannot yet be predicted with speci-
ﬁcity despite the information provided by the existing serum
markers.Thisisofprimeimportancesincedataderivedfrom
animalmodelsunderscoretheneedtoknowwhichimmuno-
logical reaction takes place at which time so as to administer
the appropriate type of immunotherapy [5, 12]. Although
various studies exist providing in-depth knowledge about
the sequence of events of the septic cascade in animals [4],
there are various drawbacks for the human situation. The
present study attempted to correlate the potency of mono-
Table 2: Serum concentrations of tumour necrosis factor-alpha
(TNFα), IL-6, IL-10, and malondialdehyde (MDA) of 51 septic pa-
tientsinrelationtothetimeofbloodsamplingfromadventoffever.
Group A
(n = 13)
<12 hours
GroupB
(n=16)
12–24hours
Group C
(n = 22)
>24 hours
Median (IQR)
TNFα (pg/mL) 9.88 (9.40) 7.23 (7.54) 7.64 (4.11)
IL-6 (pg/mL) 94.3
(225.1) 65.1 (179.2) 55.4
(120.5)
IL-10 (pg/mL) <12.5 <12.5 <12.5
MDA (μmol/mL) 0.80
(11.30) 2.87 (9.40) 4.75
(10.05)
cytes of the septic host for the ex vivo release of pro- and
anti-inﬂammatory mediators at various time intervals from
the advent of fever in cases where fever was the initial symp-
tom of the underlying septic process. To our knowledge, a
similar attempt has never been described before.
Results revealed that monocytes of septic patients were
most potent for the ex vivo release of TNFα, IL-6, IL-10, and
MDA compared to healthy donors within the ﬁrst 24 hours
upon advent of fever (Figure 1). These ﬁndings signify that
monocytes of septic hosts are still able to release a variety
of mediators when put in an ex vivo milieu. Monocytes are
probably primed in their septic environment for that pro-
duction.
T h ep a t t e r no fr e l e a s eo fm e d i a t o r sb ym o n o c y t e si sn o t
ubiquitous since MDA is mainly secreted early, TNFα late,
and IL-6 both early and late in relation to start of fever. Per-
haps safe conclusions can be drawn only for IL-6 for two
mainreasons:(a)monocytestimulationwithpatients’serum
yielded further release of IL-6 only for monocytes isolated
within the ﬁrst 12 hours from advent of fever (Figure 2), and
(b) there is a negative correlation between time lapsing from
start of fever and serum-stimulated release of IL-6 by mono-
cytes (Figure 3).
What may be the underlying mechanism of induction of
IL-6 by patients’ serum is not known and only hypothesis
can be done. Serum cytokines do not seem responsible for
that, since their levels do not diﬀer between sera sampled at
diﬀerent time intervals from advent of fever (Table 2). Fur-
thermore,caspase-3activityofmonocyteswassimilarincor-
relation to time lapsing from presence of fever, so it might
not be hypothesized that endogenous inertia of monocytes
wasa culprit. Whatevermight be the underlying mechanism,
the clinical signiﬁcance of that observation is that within the
ﬁrst 12 hours of fever, the monocytes of the septic host are
embedded in an environment promoting the release of IL-6
(Figure 2). This environment seems to be a major determi-
nant of the outcome of the septic patient. Despite the low
number of deaths among the enrolled patients, ex vivo re-
lease of IL-6 was greater among survivors compared to non-
survivors. That diﬀerence ceased to exist upon stimulation
showing that the presence of serum elicited signiﬁcant re-
lease of IL-6 from monocytes of nonsurvivors. This latter
ﬁnding becomes of particular importance when consideringMagdalini Kyriakopoulou et al. 7
data of animal studies. In experimental peritonitis in mice,
prompt administration of imipenem could signiﬁcantly de-
crease mortality with the sole exception of animals with very
high serum concentrations of IL-6 [13].
The ﬁndings of the present study are in general agree-
ment with those described in animal models of sepsis. Early
sepsis in mice is accompanied by high serum concentrations
of both pro-inﬂammatory and anti-inﬂammatory cytokines
as opposed to low serum concentrations found in late sepsis
[14]. On the same context, ex vivo release of TNFα,I L - 6 ,a n d
IL-10 by monocytes of the septic host was greater within the
ﬁrst 24 hours upon advent of fever.
In conclusion, our data revealed that fever might con-
stitute a symptom predictive of the immune function of the
septic host. Monocytes are potent for the release of pro- and
anti-inﬂammatory mediators within the ﬁrst 24 hours upon
advent of fever; serum of patients stimulates further release
of IL-6 within the ﬁrst 12 hours. These ﬁndings are in gen-
eral agreement with both experimental and clinical results
that, as antibiotics, should be administered as early as possi-
ble in the septic host [15, 16], the same may be necessary for
immunomodulatory treatment.
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